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2Novel antiretroviral drugs include protease (PR) inhibitors (e.g., atazanavir, tipranavir 
and darunavir) that block human immunodeficiency virus type 1 (HIV-1) maturation 
while showing remarkable antiviral potency on drug-resistant isolates.  However, the 
strains used as prototypes in the design of the novel drugs belong to a specific clade (i.e. 
HIV-1 – group M – subtype B), which is the most prevalent in developed countries.  At the 
same time, there is an increasing concern on the expansion of other HIV-1 clades as well 
as other related retroviruses such as HIV-2.  The HIV-2 PR is weakly inhibited by some 
PR inhibitors (e.g. amprenavir), and little is known on the mutational pathways leading to 
drug resistance in this virus.  The design of specific PR inhibitors targeting HIV-2, or 
potent drugs showing broad specificity on HIV-1 and HIV-2 clades remain as major 
challenges for the future.
Introduction
Since its first report in 1981, the acquired immunodeficiency syndrome (AIDS) has been 
continuously spreading.  As of December 2006, there were around 40 million people infected 
with the human immunodeficiency virus (HIV) in the World.  There are two main types of HIV, 
type 1 (HIV-1) and type 2 (HIV-2), with HIV-1 being the most prevalent in the worldwide 
pandemic.   The HIV-2 is mainly present in West Africa, where it was discovered in 1986 [1], 
and infects around one million people worldwide.  HIV-2 is slowly but continuously spreading 
to Europe, Asia and the Americas, reaching a significant prevalence in countries such as 
Portugal or India. In Portugal, HIV-2 accounts for approximately 4 % of the total number of 
AIDS cases (information available at http://www.insarj.pt).
3Compared with HIV-1, HIV-2 is less transmissible and less pathogenic, with lower viral 
loads while asymptomatic and a slower progression to AIDS [2].  However, cohort studies and 
clinical trials are difficult to conduct due to the smaller number of people infected with HIV-2. 
In addition, monitoring the infection is complicated by the lack of a commercially available 
assay for measurement of plasma HIV-2 viremia. Currently approved antiretroviral drugs have 
been designed against HIV-1 (its viral life cycle is shown in Figure 1), and our knowledge on 
the efficiency of those compounds on HIV-2, both in vivo and in vitro, is still incomplete.  The 
mutational patterns involved in the acquisition of drug resistance in HIV-2 strains may be 
different from those observed in HIV-1.  In some cases, the comparison of HIV-1 and HIV-2 
genotypes reveals the existence of amino acid sequence differences that have been associated 
with drug resistance in HIV-1.  These differences are responsible in part for the low accuracy of 
genotypic interpretation algorithms developed for HIV-1, in predicting HIV-2 drug resistance.  
On the other hand, recombinant virus-based susceptibility assays use HIV-1 group M subtype 
B-based vectors into which patient-derived protease (PR) and/or reverse transcriptase (RT) 
sequences are transferred [3].  
HIV-2 shows natural resistance to the three licensed non-nucleoside RT inhibitors (i.e.,
nevirapine, delavirdine and efavirenz).  In contrast, nucleoside RT inhibitors such as 
zidovudine, lamivudine, stavudine, zalcitabine and abacavir, as well as the acyclic phosphonate
tenofovir retain full activity against HIV-2 strains in phenotypic assays [4].  Since the 
introduction of potent antiretroviral drug combination therapies, PR inhibitors have contributed 
to the significant reduction of morbidity and mortality due to HIV-1 infection in developed 
countries [5].  However, the efficacy of PR inhibitors on HIV-2 has been poorly documented.
In this review, we will discuss on the differences between the inhibitor binding site of 
HIV-1 and HIV-2 PRs and interactions involved in binding currently approved PR inhibitors, 
4emphasizing on the specific mutational patterns appearing in vitro and in vivo during HIV-2 
infections.
Comparison of the HIV-1 and HIV-2 PRs
HIV PRs are homodimeric enzymes composed of two polypeptide chains of 99 residues.  HIV-
1 and HIV-2 PRs share 39-48 % identical amino acid sequences depending on the strain of 
virus being compared.  For example, the PR of the strain HIV-1HXB2 contains 48 amino acid 
residues which are conserved in the strain HIV-2ROD (Figure 2). The first detailed comparison 
of the HIV-1 and HIV-2 PR sequences and structures was made by Gustchina and Weber [6].  
A model structure of the HIV-2 PR was then generated based on the crystal structure of the
HIV-1 PR complexed with an inhibitor. As of today, there are more than two hundred crystal 
(or NMR) structures of wild-type and mutant HIV-1 PRs deposited in the Protein Data Bank
(PDB).  However, the number of HIV-2 PR structures is considerably smaller (less than 30, 
information is available at http://www.pdb.org).  Most of the HIV-2 PR structures were 
obtained with inhibitors that have not been used in AIDS therapy.   Indinavir is the only 
approved inhibitor whose structure has been solved in a complex with HIV-2 PR (PDB code 
1HSH) (Figure 3).  Despite the limited information on HIV-2 PRs, it is clear that the overall 
topology of this enzyme is very similar to that described for the HIV-1 PR. 
HIV PR homodimers contain conserved Asp residues at position 25 of each unit.  These 
Asp residues are part of the active site, which is held in a rigid position by a network of 
hydrogen bonds, known as the “fireman’s grip”.  In the absence of ligand, both PRs show 
perfect symmetry. Each subunit contains two layers of β sheets whose strands are oriented in 
an orthogonal fashion.  These structures provide a hydrophobic core. In addition to the 
fireman’s grip supporting the catalytic site, both subunits contain a flexible surface β-hairpin, 
known as the “flap” region (residues 42-58).  These structures are flexible in the absence of the 
5ligand, and close down upon binding of the inhibitor or the substrate (Figure 3).  A four-
stranded β sheet formed by the N- and C-termini (residues 1-5 and 95-99) of each subunit 
provides a series of hydrogen bonds that appear to be critical for dimerization. 
As originally suggested [6], all of the important structural elements are highly 
conserved, especially around the catalytic Asp residues (positions 23-30), as well as at a short 
region including residues 86-88 which anchor the catalytic amino acids at an appropriate 
conformation for catalysis. The highly conserved Arg-87, which resides on the α-helix 
comprising residues 87-91, forms a hydrogen bond with the side-chain of Asp-29.  This 
interaction plays a critical role in HIV-1 PR dimerization [7]. 
HIV-1 reverse transcriptase is an error-prone enzyme (reviewed in [8]).  Error rates of 
10-4 mutations per nucleotide per cycle have been reported for HIV-1.  These values are 
consistent with the extensive sequence variability observed in HIV populations.  As for HIV-1 
PR, studies on the variability of the HIV-2 PR-coding region have shown that sequence 
variation occurs mainly at surface positions, while the structurally important regions remain 
conserved [9-14] (Figure 2).  The degree of PR sequence conservation (< 1 % variability) in 
HIV-2 isolates obtained from untreated patients is around 56 %, somewhat lower than for HIV-
1 PRs that shows conservation in 68 out of 99 residues [15].  In addition, there are substantial 
differences in the location of polymorphic sites.  Thus, many of the polymorphic sites of HIV-2 
PR (e.g., at positions 17, 40, 46, 68, 79 and 91) are highly conserved in the HIV-1 PR, and 
conversely, many of the highly polymorphic sites in the HIV-1 PR [9] are highly conserved in 
the HIV-2 PR (e.g., at positions 13, 37, 63, 64, 69 and 93).
The substrate binding pockets of HIV-1 and HIV-2 PRs are formed by residues 8, 23, 
25, 27-30, 32, 47-50, 53, 76, 80-82 and 84. A schematic diagram of the substrate-binding site of 
HIV-2 PR showing the modelled interactions of the bound substrate representing the MA↓CA 
cleavage site is given in Figure 4. The substrate binds to either HIV-1 or HIV-2 PRs in an 
6extended β conformation and it is anchored by several hydrogen bonds. Substrate-based 
inhibitors bind in a very similar manner. The enzyme recognizes at least seven substrate 
residues, from P4 to P3’ (Figure 4). Although these binding sites have been individually 
characterized based on detailed cleavage specificity studies, as well as HIV PR-inhibitor crystal 
structures, interactions defining PR specificity appear to show very strong sequence context 
dependence (reviewed in [16]).  Importantly, there are only four residues involved in ligand 
binding which are different between HIV-1 and HIV-2 PRs. These residues are all involved in 
conservative substitutions that represent a loss or gain of methyl groups. Thus, Val-32, Ile-47, 
Leu-76 and Val-82 in HIV-1 PR change to Ile-32, Val-47, Met-76 and Ile-82 in the HIV-2 PR, 
respectively (Figures 2 and 4).  Detailed analysis of the PR cleavage specificity, using 
oligopeptide substrates containing single-amino-acid substitutions in a substrate mimicking an 
HIV-1 Gag cleavage site combined with modelling studies, have revealed the importance of 
these residues to explain differences in substrate specificity between HIV-1 and HIV-2 PRs
[17,18]. 
Clinically approved HIV-1 PR inhibitors that are also utilized in anti-HIV-2 therapy
Currently there are nine clinically approved inhibitors developed against HIV-1 PR. These
drugs are saquinavir, ritonavir, indinavir, amprenavir (also licensed as fosamprenavir),
nelfinavir, lopinavir, atazanavir, tipranavir and darunavir (Figure 5). All of them except 
tipranavir, are compounds whose molecular structure mimics the structure of the PR substrates. 
Interactions between the PR and those inhibitors are mainly hydrophobic, and therefore, similar 
to those involved in enzyme-substrate interactions. Typically, PR inhibitors contain a phenyl 
residue at P1 or P1´ positions. Another common feature of most PR inhibitors is that they 
contain a nonhydrolyzable transition-state mimic (e.g., a hydoxyethylamine group at the site 
corresponding to the cleavable bond in the substrates).  Saquinavir was the first HIV-1 PR 
7inhibitor that was licensed for therapy. Its chemical structure resembles an HIV-1 cleavage site
(see Figure 5), where the Pro residue at position P1´ was replaced by a saturated isoquinoline 
ring. Indinavir and nelfinavir also mimic the characteristic Tyr(Phe)↓Pro cleavage site.  
Ritonavir was developed from a symmetric molecule, while amprenavir is a sulfonamide 
compound. Lopinavir was the first second-generation PR inhibitor. Its core is identical to that of 
ritonavir, and it was designed to diminish the interactions of the inhibitor with Val-82, a residue 
that is frequently mutated in HIV-1 drug-resistant strains. New, second-generation inhibitors, 
such as atazanavir or darunavir, have been designed to combat drug-resistant mutants mainly by 
increasing the number of polar interactions with main chain atoms of the PR [19].  At present, 
ritonavir is used only at low doses, to improve the pharmacokinetic properties of 
coadministered PR inhibitors.  
Molecular basis of HIV-2 PR drug resistance
The molecular basis of HIV-1 drug resistance have been studied extensively. An important 
conclusion obtained from the analysis of crystal structures and kinetic studies with HIV PRs 
was that most amino acid changes that confer drug resistance in HIV-1 involve mutations at 
positions that contact the inhibitor but not the substrates. Therefore, resistant enzymes are
capable of catalysing the cleavages required for infection but are not inhibited by the drugs
[20]. 
In contrast to HIV-1, very few data are available about the impact of primary or 
secondary PR mutations on both viral fitness and the level of drug resistance in HIV-2 
infection. Nevertheless, based on the similar structure of the two enzymes, most of the 
knowledge obtained with HIV-1 can be utilized also in HIV-2 to predict the molecular effect of 
mutations observed in drug resistance. 
8In addition to primary drug-resistance mutations involving residues of the HIV-1 PR 
ligand-binding pockets, which coincide with amino acid differences between HIV-1 and HIV-2 
PRs (i.e., V32I, I47V, L76M and V82I), secondary mutations may interfere with inhibitor 
binding through indirect perturbations of the binding site, or by influencing the enzyme activity 
through changing their conformational flexibility or PR dimerization properties. The same
effects are expected for HIV-2 PR. Therefore, the presence of L10I/V, G16E, K20V, L33V, 
E35G, M36I/V, M46I/V, Q58E, I62V, A71I/V, G73A and I93L in the HIV-2 PR sequence 
(Figure 2) could also have an important effect on drug resistance, since the same residues are 
selected in the HIV-1 PR under treatment with PR inhibitors [21,22]. 
HIV-2 susceptibility to PR inhibitors in cell culture assays
Saquinavir, indinavir and ritonavir were found to be equally active against HIV-1 and the HIV-
2 strains ROD and EHO, in conventional MT-4/MTT susceptibility assays [4], although others 
have reported that ritonavir was less effective on HIV-2, in assays carried out with peripheral 
blood mononuclear cells (PBMCs) or MT-2 cells [23,24].  On the other hand, HIV-2 ROD and 
EHO isolates showed IC50 values for nelfinavir which were around 1.5 to 4 times higher than 
the ones obtained with reference HIV-1 strains [4,23,24].  The relatively weak inhibitory effect
of nelfinavir (approx. 4.5-fold increase of the IC50 for the inhibitor) on HIV-2 has been recently
confirmed in assays carried out with uninfected cord blood mononuclear cells, and strains CBL-
20, CBL-23 and MVP-15132 [13].  In this study, authors also showed that lopinavir was an 
effective inhibitor of HIV-2 strains, an observation in agreement with preliminary data reported 
by others [25,26].
Natural resistance to amprenavir has been demonstrated for several HIV-2 strains (e.g. 
ROD, EHO) [4,13,23-26].  In phenotypic assays, HIV-2 strains showed IC50s which were 8.8 to 
30 times higher than those obtained with wild-type HIV-1 clones.  
9Novel PR inhibitors, such as tipranavir, atazanavir or darunavir have been selected for 
their lack of cross-resistance with other PR inhibitors, but also for their higher specificity on the 
HIV-1 enzyme.  Therefore, a loss of potency on HIV-2 strains would not be surprising.  
Although, in some cases, available information is still preliminary, HIV-2 strains appear to be 
resistant to atazanavir [25-27], but susceptible to darunavir [24,26].  HIV-2 resistance to 
tipranavir has been reported by several groups.  Published IC50 values for this inhibitor were 2 
to 9 times higher than those reported for HIV-1 strains [13,25,26].
Development of resistance in cell culture
As indicated above, several amino acid residues of the wild-type HIV-2 PR are also selected 
under drug pressure in the HIV-1 PR [22].  However, unlike in the case of HIV-1, information 
regarding selection of drug-resistant HIV-2 strains in vitro is scarce.  For several inhibitors, the 
mutational patterns involved in HIV-2 resistance are different from those observed with HIV-1. 
Thus, I82L develops quickly in HIV-2 strains under tipranavir resistance [13], while conferring 
high-level resistance to the inhibitor in phenotypic assays [13,28].  Cross-resistance between 
tipranavir and lopinavir due to the presence of Leu-82 was observed in phenotypic assays [13].  
Unlike in the case of HIV-2, HIV-1 PR variants containing Leu-82 emerge as the result of 
secondary mutations in selection experiments carried out in the presence of tipranavir [29]. 
The substitution of Met for Ile-54 (I54M) has been observed in HIV-2 strains selected in 
vitro in the presence of amprenavir, nelfinavir, and indinavir [13].  In the case of indinavir, it 
develops quickly, while conferring high-level resistance to amprenavir, nelfinavir and lopinavir 
in phenotypic assays [13,28].  However, HIV-2 strains carrying the I54M substitution in their 
PR remained susceptible to saquinavir [28].
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HIV-1 and HIV-2 show remarkable differences in their mutational pathways leading to 
nelfinavir resistance.  While the emergence of D30N appears to be relevant for the acquisition 
of nelfinavir resistance in HIV-1 [30], this amino acid change was not observed in selection 
experiments carried out with HIV-2 strains.  Instead, I82F alone or I54M alone or in 
combination with L90M or L99F were commonly identified in nelfinavir-resistant HIV-2 
strains selected in cell culture [13].  I82F confers high-level resistance to indinavir and 
lopinavir in phenotypic assays, while combinations of I54M with other mutations such as I84V, 
L90M or L99F may confer resistance to several PR inhibitors such as amprenavir, indinavir, 
nelfinavir, tipranavir and lopinavir.  The presence of L99F in combination with V62A has been 
observed in indinavir-resistant HIV-2 variants derived from the CBL-23 strain.  The 
V62A/L99F combination confers high-level resistance to lopinavir and moderate resistance to 
nelfinavir and indinavir in phenotypic assays [13].  
Lopinavir-resistant HIV-2 variants obtained after passage of the virus in the presence of
the drug (up to 1 μM) contained the V47A substitution in the viral PR, often accompanied by 
D17N [31].  D17N appears to have a minor effect on resistance and fitness [31].  However, the 
V47A mutation, which is also frequently found in lopinavir-treated patients [28,32], decreases 
lopinavir susceptibility by >10-fold in phenotypic assays [28,31].  In contrast, V47A has a 
minor effect on ritonavir, nelfinavir, tipranavir and darunavir resistance. Isolates containing the 
V47A mutation were hypersusceptible to saquinavir [28,31].  For other inhibitors, conflicting 
results have been reported. Rodés et al. [28] have shown that V47A confers amprenavir and 
indinavir resistance, while having no effect on atazanavir susceptibility.  In contrast, Masse et 
al. [31] found that amprenavir and indinavir susceptibilities were not influenced by the 
mutation, but atazanavir susceptibility was reduced by 10-fold when V47A was introduced in 
the sequence background of the HIV-2ROD strain. 
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In HIV-1, I47V emerges as a major lopinavir resistance mutation [33], since two 
nucleotide changes are required to obtain the I47A substitution.  However, I47A has been 
identified in HIV-1-infected patients demonstrating evolution of lopinavir resistance, although 
in combination with V32I (a characteristic mutation found in the HIV-2 PR) [34]. 
Sequence polymorphisms and selection of mutations in HIV-2-infected patients treated 
with PR inhibitors
In the HIV-1 PR, the substitution M46I has been identified as a relevant mutation in the 
acquisition of resistance to indinavir [35], ritonavir [36], nelfinavir [37] and lopinavir [34,38].  
In the HIV-2 PR, 46I is predominant in drug-naïve individuals, where it has been found in >89 
% of the isolates obtained from infected patients [10,12,14].  However, HIV-2 strains are 
susceptible to indinavir and ritonavir in vitro [4].  Although the efficacy of those drugs on HIV-
2 has been poorly documented, clinical studies involving a relatively large number of patients 
showed that there is a significant association between the emergence of mutation I82F and
ritonavir or indinavir therapy [11,39].  Interestingly, the presence of L90M has been reported to 
appear in HIV-2 from patients receiving saquinavir, indinavir, ritonavir or nelfinavir, usually in 
combination with other relevant mutations (i.e. I54M, I54L, V71I, I82F or I84V) 
[9,11,32,40,41].
In the case of nelfinavir, L90M appears to play a major role in the acquisition of 
resistance, as occurs with HIV-1 subtype C viruses [42], and unlike in the case of HIV-1 
subtype B, where the combination D30N/N88S mediates the acquisition of high-level resistance 
to the inhibitor, in the absence of previous treatments with PR inhibitors [37].
In addition, a number of changes at positions rarely associated with HIV-1 drug 
resistance appear to be selected in HIV-2-infected patients treated with PR inhibitors.  
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Examples are K7R, V62A and V62T, or L99F [9].  K7R appeared in patients treated with 
saquinavir, ritonavir or lopinavir and in those individuals, the substitution was associated with 
M46I but never with L90M.  L99F has been found in patients failing treatment with ritonavir 
and nelfinavir, although in combination with S43I, K45R, I54M, V71I and A92T [43].   
Although V47A has been identified as the major lopinavir resistance mutation both in vivo and 
in vitro [28,31,32], the presence of K45R and I64V in viral isolates from patients failing 
lopinavir treatment has been reported in two different studies [28,42].  The significance of those 
mutations, as well as others which are found less frequently in those patients (e.g. S19P, G48A, 
I50V) is still uncertain.  
Conclusions
The susceptibility of the HIV-2 PR to antiretroviral drugs appears to be determined by amino 
acid substitutions other than those contributing to antiretroviral drug resistance in HIV-1.  As 
discussed above, sequence differences between the HIV-1 and HIV-2 PRs are expected to have 
a large impact on the efficiency of the antiviral treatments.  While amprenavir shows poor 
efficiency on HIV-2, the lower activity of nelfinavir, tipranavir and atazanavir, facilitates the 
development of resistance to those inhibitors.  Inhibitors developed as drugs targeting heavily 
mutated HIV-1 PRs, such as lopinavir or tipranavir, are probably less effective on the HIV-2 
PR due to the different sequence background that in some cases, would facilitate the rapid 
development of resistance, due to the emergence of single-nucleotide mutations that confer 
high-level resistance to the inhibitor.  Examples are V47A in the case of ritonavir-boosted 
lopinavir therapy [28,31,32], or I82L in the case of treatment with ritonavir-boosted tipranavir 
[13].  In addition to the limited knowledge about how to treat and interpret results from 
genotypic resistance assays in HIV-2 infection, therapeutic options might be limited in the long 
term due to inefficacy of several PR inhibitors (i.e. poor inhibitory activity and easy 
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development of resistance).  In this scenario, the design and development of novel specific 
drugs targeting the HIV-2 PR will gain importance, particularly with an increasing prevalence 
of HIV-2 infections.  Our current knowledge of the interactions between the HIV-1 PR and its 
inhibitors should provide a solid framework for the development of specific inhibitors of the 
HIV-2 PR through rational design.  In this context, the available crystal structures of HIV-2 
PR/inhibitor complexes should be an important aid to achieve that goal.
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LEGENDS TO FIGURES
Figure 1.  Targets for therapeutic intervention in the HIV life cycle.  Currently approved 
antiretroviral drugs block HIV infection at different steps of the viral life cycle: (i) virus entry
through their interaction with gp120 or gp41(i.e. maraviroc and enfuvirtide, respectively); (ii) 
reverse transcription (i.e. RT inhibitors); (iii) integration (i.e. integrase (IN) inhibitors such as 
raltegravir), and (iv) maturation (i.e. PR inhibitors that block the conversion of immature virus 
into mature infectious virions).
Figure 2.  Amino acid sequence comparison of HIV-1 and HIV-2 proteases of reference strains 
HXB2 (HIV-1) and ROD (HIV-2).  Identical residues are marked with red asterisks. Conserved 
structurally important regions are highlighted on a grey background.  Box A corresponds to the 
dimerization domain, box B to the active site region and the C-terminal triad, and box C 
indicates the flap region. Amino acid differences between HIV-1 and HIV-2 PRs at positions 
relevant for resistance to HIV-1 PR inhibitors are indicated [22]. Major and minor PR inhibitor 
resistance mutations occur at the positions highlighted in yellow and light blue, respectively.  
Highly polymorphic positions (≥ 20 % sequence variation) in the PR of HIV-2 subtype A 
isolates are indicated with blue letters.  HIV-2 PR residues appearing with a frequency above 4 
% are indicated below the reference sequence. The analysis of polymorphic sites in the HIV-2 
PR was based on 164 published sequences of HIV-2 isolates obtained from naïve patients [9-
14]. 
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Figure 3.  Crystallographic structures of human immunodeficiency virus proteases complexed 
with indinavir.  In panels (A) and (B), the two polypeptide chains of the human 
immunodeficiency virus type 2 protease are represented as ribbon diagrams (red and green).  
The inhibitor is shown in yellow using a CPK model.  The side chains chains of catalytic 
residues (Asp-25 in both subunits) are shown in blue. Atom coordinates were taken from PDB 
file 1HSH. Side and top views are shown in (A) and (B), respectively. (C) Crystal structure of 
human immunodeficiency virus type 1 protease complexed with indinavir (PDB file 1HSG). 
Figure 4.  Residues forming the substrate binding pocket of HIV proteases.  Schematic 
representation of an oligopeptide (SQNY↓PIV) that mimicks the HIV-1 Gag MA↓CA cleavage 
site, showing its potential interactions with the substrate binding site of the HIV-2 protease. 
Primes indicate residues in the second subunit of the dimer.  The relative size of each substrate 
is illustrated by the area enclosed by the curved line around each substrate side chain. Substrate 
binding residues that are commonly observed in HIV isolates with high-level resistance to one 
or more drugs are boxed, and the residue found in the wild-type HIV-1 is shown between 
parentheses.  The amino acid residues interacting with ritonavir, lopinavir and darunavir 
(inhibitors shown in white) in the crystal structures of HIV-1 PR complexes are indicated 
below.  Sequence positions of residues at less than 4 Å from the inhibitor are given.  Side 
chains and their corresponding amino acid are indicated for those residues located at less than 
3.5 Å of the inhibitor.     
Figure 5.  Inhibitors of human immunodeficiency virus type 1 (HIV-1) protease that are 
licensed to treat AIDS and AIDS-related malignancies.
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2Novel antiretroviral drugs include protease (PR) inhibitors (e.g., atazanavir, tipranavir 
and darunavir) that block human immunodeficiency virus type 1 (HIV-1) maturation 
while showing remarkable antiviral potency on drug-resistant isolates.  However, the 
strains used as prototypes in the design of the novel drugs belong to a specific clade (i.e. 
HIV-1 – group M – subtype B), which is the most prevalent in developed countries.  At the 
same time, there is an increasing concern on the expansion of other HIV-1 clades as well 
as other related retroviruses such as HIV-2.  The HIV-2 PR is weakly inhibited by some 
PR inhibitors (e.g. amprenavir), and little is known on the mutational pathways leading to 
drug resistance in this virus.  The design of specific PR inhibitors targeting HIV-2, or 
potent drugs showing broad specificity on HIV-1 and HIV-2 clades remain as major 
challenges for the future.
Introduction
Since its first report in 1981, the acquired immunodeficiency syndrome (AIDS) has been 
continuously spreading.  As of December 2006, there were around 40 million people infected 
with the human immunodeficiency virus (HIV) in the World.  There are two main types of HIV, 
type 1 (HIV-1) and type 2 (HIV-2), with HIV-1 being the most prevalent in the worldwide 
pandemic.   The HIV-2 is mainly present in West Africa, where it was discovered in 1986 [1], 
and infects around one million people worldwide.  HIV-2 is slowly but continuously spreading 
to Europe, Asia and the Americas, reaching a significant prevalence in countries such as 
Portugal or India. In Portugal, HIV-2 accounts for approximately 4 % of the total number of 
AIDS cases (information available at http://www.insarj.pt).
3Compared with HIV-1, HIV-2 is less transmissible and less pathogenic, with lower viral 
loads while asymptomatic and a slower progression to AIDS [2].  However, cohort studies and 
clinical trials are difficult to conduct due to the smaller number of people infected with HIV-2. 
In addition, monitoring the infection is complicated by the lack of a commercially available 
assay for measurement of plasma HIV-2 viremia. Currently approved antiretroviral drugs have 
been designed against HIV-1 (its viral life cycle is shown in Figure 1), and our knowledge on 
the efficiency of those compounds on HIV-2, both in vivo and in vitro, is still incomplete.  The 
mutational patterns involved in the acquisition of drug resistance in HIV-2 strains may be 
different from those observed in HIV-1.  In some cases, the comparison of HIV-1 and HIV-2 
genotypes reveals the existence of amino acid sequence differences that have been associated 
with drug resistance in HIV-1.  These differences are responsible in part for the low accuracy of 
genotypic interpretation algorithms developed for HIV-1, in predicting HIV-2 drug resistance.  
On the other hand, recombinant virus-based susceptibility assays use HIV-1 group M subtype 
B-based vectors into which patient-derived protease (PR) and/or reverse transcriptase (RT) 
sequences are transferred [3].  
HIV-2 shows natural resistance to the three licensed non-nucleoside RT inhibitors (i.e.,
nevirapine, delavirdine and efavirenz).  In contrast, nucleoside RT inhibitors such as 
zidovudine, lamivudine, stavudine, zalcitabine and abacavir, as well as the acyclic phosphonate
tenofovir retain full activity against HIV-2 strains in phenotypic assays [4].  Since the 
introduction of potent antiretroviral drug combination therapies, PR inhibitors have contributed 
to the significant reduction of morbidity and mortality due to HIV-1 infection in developed 
countries [5].  However, the efficacy of PR inhibitors on HIV-2 has been poorly documented.
In this review, we will discuss on the differences between the inhibitor binding site of 
HIV-1 and HIV-2 PRs and interactions involved in binding currently approved PR inhibitors, 
4emphasizing on the specific mutational patterns appearing in vitro and in vivo during HIV-2 
infections.
Comparison of the HIV-1 and HIV-2 PRs
HIV PRs are homodimeric enzymes composed of two polypeptide chains of 99 residues.  HIV-
1 and HIV-2 PRs share 39-48 % identical amino acid sequences depending on the strain of 
virus being compared.  For example, the PR of the strain HIV-1HXB2 contains 48 amino acid 
residues which are conserved in the strain HIV-2ROD (Figure 2). The first detailed comparison 
of the HIV-1 and HIV-2 PR sequences and structures was made by Gustchina and Weber [6].  
A model structure of the HIV-2 PR was then generated based on the crystal structure of the
HIV-1 PR complexed with an inhibitor. As of today, there are more than two hundred crystal 
(or NMR) structures of wild-type and mutant HIV-1 PRs deposited in the Protein Data Bank
(PDB).  However, the number of HIV-2 PR structures is considerably smaller (less than 30, 
information is available at http://www.pdb.org).  Most of the HIV-2 PR structures were 
obtained with inhibitors that have not been used in AIDS therapy.   Indinavir is the only 
approved inhibitor whose structure has been solved in a complex with HIV-2 PR (PDB code 
1HSH) (Figure 3).  Despite the limited information on HIV-2 PRs, it is clear that the overall 
topology of this enzyme is very similar to that described for the HIV-1 PR. 
HIV PR homodimers contain conserved Asp residues at position 25 of each unit.  These 
Asp residues are part of the active site, which is held in a rigid position by a network of 
hydrogen bonds, known as the “fireman’s grip”.  In the absence of ligand, both PRs show 
perfect symmetry. Each subunit contains two layers of β sheets whose strands are oriented in 
an orthogonal fashion.  These structures provide a hydrophobic core. In addition to the 
fireman’s grip supporting the catalytic site, both subunits contain a flexible surface β-hairpin, 
known as the “flap” region (residues 42-58).  These structures are flexible in the absence of the 
5ligand, and close down upon binding of the inhibitor or the substrate (Figure 3).  A four-
stranded β sheet formed by the N- and C-termini (residues 1-5 and 95-99) of each subunit 
provides a series of hydrogen bonds that appear to be critical for dimerization. 
As originally suggested [6], all of the important structural elements are highly 
conserved, especially around the catalytic Asp residues (positions 23-30), as well as at a short 
region including residues 86-88 which anchor the catalytic amino acids at an appropriate 
conformation for catalysis. The highly conserved Arg-87, which resides on the α-helix 
comprising residues 87-91, forms a hydrogen bond with the side-chain of Asp-29.  This 
interaction plays a critical role in HIV-1 PR dimerization [7]. 
HIV-1 reverse transcriptase is an error-prone enzyme (reviewed in [8]).  Error rates of 
10-4 mutations per nucleotide per cycle have been reported for HIV-1.  These values are 
consistent with the extensive sequence variability observed in HIV populations.  As for HIV-1 
PR, studies on the variability of the HIV-2 PR-coding region have shown that sequence 
variation occurs mainly at surface positions, while the structurally important regions remain 
conserved [9-14] (Figure 2).  The degree of PR sequence conservation (< 1 % variability) in 
HIV-2 isolates obtained from untreated patients is around 56 %, somewhat lower than for HIV-
1 PRs that shows conservation in 68 out of 99 residues [15].  In addition, there are substantial 
differences in the location of polymorphic sites.  Thus, many of the polymorphic sites of HIV-2 
PR (e.g., at positions 17, 40, 46, 68, 79 and 91) are highly conserved in the HIV-1 PR, and 
conversely, many of the highly polymorphic sites in the HIV-1 PR [9] are highly conserved in 
the HIV-2 PR (e.g., at positions 13, 37, 63, 64, 69 and 93).
The substrate binding pockets of HIV-1 and HIV-2 PRs are formed by residues 8, 23, 
25, 27-30, 32, 47-50, 53, 76, 80-82 and 84. A schematic diagram of the substrate-binding site of 
HIV-2 PR showing the modelled interactions of the bound substrate representing the MA↓CA 
cleavage site is given in Figure 4. The substrate binds to either HIV-1 or HIV-2 PRs in an 
6extended β conformation and it is anchored by several hydrogen bonds. Substrate-based 
inhibitors bind in a very similar manner. The enzyme recognizes at least seven substrate 
residues, from P4 to P3’ (Figure 4). Although these binding sites have been individually 
characterized based on detailed cleavage specificity studies, as well as HIV PR-inhibitor crystal 
structures, interactions defining PR specificity appear to show very strong sequence context 
dependence (reviewed in [16]).  Importantly, there are only four residues involved in ligand 
binding which are different between HIV-1 and HIV-2 PRs. These residues are all involved in 
conservative substitutions that represent a loss or gain of methyl groups. Thus, Val-32, Ile-47, 
Leu-76 and Val-82 in HIV-1 PR change to Ile-32, Val-47, Met-76 and Ile-82 in the HIV-2 PR, 
respectively (Figures 2 and 4).  Detailed analysis of the PR cleavage specificity, using 
oligopeptide substrates containing single-amino-acid substitutions in a substrate mimicking an 
HIV-1 Gag cleavage site combined with modelling studies, have revealed the importance of 
these residues to explain differences in substrate specificity between HIV-1 and HIV-2 PRs
[17,18]. 
Clinically approved HIV-1 PR inhibitors that are also utilized in anti-HIV-2 therapy
Currently there are nine clinically approved inhibitors developed against HIV-1 PR. These
drugs are saquinavir, ritonavir, indinavir, amprenavir (also licensed as fosamprenavir),
nelfinavir, lopinavir, atazanavir, tipranavir and darunavir (Figure 5). All of them except 
tipranavir, are compounds whose molecular structure mimics the structure of the PR substrates. 
Interactions between the PR and those inhibitors are mainly hydrophobic, and therefore, similar 
to those involved in enzyme-substrate interactions. Typically, PR inhibitors contain a phenyl 
residue at P1 or P1´ positions. Another common feature of most PR inhibitors is that they 
contain a nonhydrolyzable transition-state mimic (e.g., a hydoxyethylamine group at the site 
corresponding to the cleavable bond in the substrates).  Saquinavir was the first HIV-1 PR 
7inhibitor that was licensed for therapy. Its chemical structure resembles an HIV-1 cleavage site
(see Figure 5), where the Pro residue at position P1´ was replaced by a saturated isoquinoline 
ring. Indinavir and nelfinavir also mimic the characteristic Tyr(Phe)↓Pro cleavage site.  
Ritonavir was developed from a symmetric molecule, while amprenavir is a sulfonamide 
compound. Lopinavir was the first second-generation PR inhibitor. Its core is identical to that of 
ritonavir, and it was designed to diminish the interactions of the inhibitor with Val-82, a residue 
that is frequently mutated in HIV-1 drug-resistant strains. New, second-generation inhibitors, 
such as atazanavir or darunavir, have been designed to combat drug-resistant mutants mainly by 
increasing the number of polar interactions with main chain atoms of the PR [19].  At present, 
ritonavir is used only at low doses, to improve the pharmacokinetic properties of 
coadministered PR inhibitors.  
Molecular basis of HIV-2 PR drug resistance
The molecular basis of HIV-1 drug resistance have been studied extensively. An important 
conclusion obtained from the analysis of crystal structures and kinetic studies with HIV PRs 
was that most amino acid changes that confer drug resistance in HIV-1 involve mutations at 
positions that contact the inhibitor but not the substrates. Therefore, resistant enzymes are
capable of catalysing the cleavages required for infection but are not inhibited by the drugs
[20]. 
In contrast to HIV-1, very few data are available about the impact of primary or 
secondary PR mutations on both viral fitness and the level of drug resistance in HIV-2 
infection. Nevertheless, based on the similar structure of the two enzymes, most of the 
knowledge obtained with HIV-1 can be utilized also in HIV-2 to predict the molecular effect of 
mutations observed in drug resistance. 
8In addition to primary drug-resistance mutations involving residues of the HIV-1 PR 
ligand-binding pockets, which coincide with amino acid differences between HIV-1 and HIV-2 
PRs (i.e., V32I, I47V, L76M and V82I), secondary mutations may interfere with inhibitor 
binding through indirect perturbations of the binding site, or by influencing the enzyme activity 
through changing their conformational flexibility or PR dimerization properties. The same
effects are expected for HIV-2 PR. Therefore, the presence of L10I/V, G16E, K20V, L33V, 
E35G, M36I/V, M46I/V, Q58E, I62V, A71I/V, G73A and I93L in the HIV-2 PR sequence 
(Figure 2) could also have an important effect on drug resistance, since the same residues are 
selected in the HIV-1 PR under treatment with PR inhibitors [21,22].
HIV-2 susceptibility to PR inhibitors in cell culture assays
Saquinavir, indinavir and ritonavir were found to be equally active against HIV-1 and the HIV-
2 strains ROD and EHO, in conventional MT-4/MTT susceptibility assays [4], although others 
have reported that ritonavir was less effective on HIV-2, in assays carried out with peripheral 
blood mononuclear cells (PBMCs) or MT-2 cells [23,24].  On the other hand, HIV-2 ROD and 
EHO isolates showed IC50 values for nelfinavir which were around 1.5 to 4 times higher than 
the ones obtained with reference HIV-1 strains [4,23,24].  The relatively weak inhibitory effect
of nelfinavir (approx. 4.5-fold increase of the IC50 for the inhibitor) on HIV-2 has been recently
confirmed in assays carried out with uninfected cord blood mononuclear cells, and strains CBL-
20, CBL-23 and MVP-15132 [13].  In this study, authors also showed that lopinavir was an 
effective inhibitor of HIV-2 strains, an observation in agreement with preliminary data reported 
by others [25,26].
Natural resistance to amprenavir has been demonstrated for several HIV-2 strains (e.g. 
ROD, EHO) [4,13,23-26].  In phenotypic assays, HIV-2 strains showed IC50s which were 8.8 to 
30 times higher than those obtained with wild-type HIV-1 clones.  
9Novel PR inhibitors, such as tipranavir, atazanavir or darunavir have been selected for 
their lack of cross-resistance with other PR inhibitors, but also for their higher specificity on the 
HIV-1 enzyme.  Therefore, a loss of potency on HIV-2 strains would not be surprising.  
Although, in some cases, available information is still preliminary, HIV-2 strains appear to be 
resistant to atazanavir [25-27], but susceptible to darunavir [24,26].  HIV-2 resistance to 
tipranavir has been reported by several groups.  Published IC50 values for this inhibitor were 2 
to 9 times higher than those reported for HIV-1 strains [13,25,26].
Development of resistance in cell culture
As indicated above, several amino acid residues of the wild-type HIV-2 PR are also selected 
under drug pressure in the HIV-1 PR [22].  However, unlike in the case of HIV-1, information 
regarding selection of drug-resistant HIV-2 strains in vitro is scarce.  For several inhibitors, the 
mutational patterns involved in HIV-2 resistance are different from those observed with HIV-1. 
Thus, I82L develops quickly in HIV-2 strains under tipranavir resistance [13], while conferring 
high-level resistance to the inhibitor in phenotypic assays [13,28].  Cross-resistance between 
tipranavir and lopinavir due to the presence of Leu-82 was observed in phenotypic assays [13].  
Unlike in the case of HIV-2, HIV-1 PR variants containing Leu-82 emerge as the result of 
secondary mutations in selection experiments carried out in the presence of tipranavir [29]. 
The substitution of Met for Ile-54 (I54M) has been observed in HIV-2 strains selected in 
vitro in the presence of amprenavir, nelfinavir, and indinavir [13].  In the case of indinavir, it 
develops quickly, while conferring high-level resistance to amprenavir, nelfinavir and lopinavir 
in phenotypic assays [13,28].  However, HIV-2 strains carrying the I54M substitution in their 
PR remained susceptible to saquinavir [28].
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HIV-1 and HIV-2 show remarkable differences in their mutational pathways leading to 
nelfinavir resistance.  While the emergence of D30N appears to be relevant for the acquisition 
of nelfinavir resistance in HIV-1 [30], this amino acid change was not observed in selection 
experiments carried out with HIV-2 strains.  Instead, I82F alone or I54M alone or in 
combination with L90M or L99F were commonly identified in nelfinavir-resistant HIV-2 
strains selected in cell culture [13].  I82F confers high-level resistance to indinavir and 
lopinavir in phenotypic assays, while combinations of I54M with other mutations such as I84V, 
L90M or L99F may confer resistance to several PR inhibitors such as amprenavir, indinavir, 
nelfinavir, tipranavir and lopinavir.  The presence of L99F in combination with V62A has been 
observed in indinavir-resistant HIV-2 variants derived from the CBL-23 strain.  The 
V62A/L99F combination confers high-level resistance to lopinavir and moderate resistance to 
nelfinavir and indinavir in phenotypic assays [13].  
Lopinavir-resistant HIV-2 variants obtained after passage of the virus in the presence of
the drug (up to 1 μM) contained the V47A substitution in the viral PR, often accompanied by 
D17N [31].  D17N appears to have a minor effect on resistance and fitness [31].  However, the 
V47A mutation, which is also frequently found in lopinavir-treated patients [28,32], decreases 
lopinavir susceptibility by >10-fold in phenotypic assays [28,31].  In contrast, V47A has a 
minor effect on ritonavir, nelfinavir, tipranavir and darunavir resistance. Isolates containing the 
V47A mutation were hypersusceptible to saquinavir [28,31].  For other inhibitors, conflicting 
results have been reported. Rodés et al. [28] have shown that V47A confers amprenavir and 
indinavir resistance, while having no effect on atazanavir susceptibility.  In contrast, Masse et 
al. [31] found that amprenavir and indinavir susceptibilities were not influenced by the 
mutation, but atazanavir susceptibility was reduced by 10-fold when V47A was introduced in 
the sequence background of the HIV-2ROD strain. 
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In HIV-1, I47V emerges as a major lopinavir resistance mutation [33], since two 
nucleotide changes are required to obtain the I47A substitution.  However, I47A has been 
identified in HIV-1-infected patients demonstrating evolution of lopinavir resistance, although 
in combination with V32I (a characteristic mutation found in the HIV-2 PR) [34]. 
Sequence polymorphisms and selection of mutations in HIV-2-infected patients treated 
with PR inhibitors
In the HIV-1 PR, the substitution M46I has been identified as a relevant mutation in the 
acquisition of resistance to indinavir [35], ritonavir [36], nelfinavir [37] and lopinavir [34,38].  
In the HIV-2 PR, 46I is predominant in drug-naïve individuals, where it has been found in >89 
% of the isolates obtained from infected patients [10,12,14].  However, HIV-2 strains are 
susceptible to indinavir and ritonavir in vitro [4].  Although the efficacy of those drugs on HIV-
2 has been poorly documented, clinical studies involving a relatively large number of patients 
showed that there is a significant association between the emergence of mutation I82F and
ritonavir or indinavir therapy [11,39].  Interestingly, the presence of L90M has been reported to 
appear in HIV-2 from patients receiving saquinavir, indinavir, ritonavir or nelfinavir, usually in 
combination with other relevant mutations (i.e. I54M, I54L, V71I, I82F or I84V) 
[9,11,32,40,41].
In the case of nelfinavir, L90M appears to play a major role in the acquisition of 
resistance, as occurs with HIV-1 subtype C viruses [42], and unlike in the case of HIV-1 
subtype B, where the combination D30N/N88S mediates the acquisition of high-level resistance 
to the inhibitor, in the absence of previous treatments with PR inhibitors [37].
In addition, a number of changes at positions rarely associated with HIV-1 drug 
resistance appear to be selected in HIV-2-infected patients treated with PR inhibitors.  
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Examples are K7R, V62A and V62T, or L99F [9].  K7R appeared in patients treated with 
saquinavir, ritonavir or lopinavir and in those individuals, the substitution was associated with 
M46I but never with L90M.  L99F has been found in patients failing treatment with ritonavir 
and nelfinavir, although in combination with S43I, K45R, I54M, V71I and A92T [43].   
Although V47A has been identified as the major lopinavir resistance mutation both in vivo and 
in vitro [28,31,32], the presence of K45R and I64V in viral isolates from patients failing 
lopinavir treatment has been reported in two different studies [28,42].  The significance of those 
mutations, as well as others which are found less frequently in those patients (e.g. S19P, G48A, 
I50V) is still uncertain.  
Conclusions
The susceptibility of the HIV-2 PR to antiretroviral drugs appears to be determined by amino 
acid substitutions other than those contributing to antiretroviral drug resistance in HIV-1.  As 
discussed above, sequence differences between the HIV-1 and HIV-2 PRs are expected to have 
a large impact on the efficiency of the antiviral treatments.  While amprenavir shows poor 
efficiency on HIV-2, the lower activity of nelfinavir, tipranavir and atazanavir, facilitates the 
development of resistance to those inhibitors.  Inhibitors developed as drugs targeting heavily 
mutated HIV-1 PRs, such as lopinavir or tipranavir, are probably less effective on the HIV-2 
PR due to the different sequence background that in some cases, would facilitate the rapid 
development of resistance, due to the emergence of single-nucleotide mutations that confer 
high-level resistance to the inhibitor.  Examples are V47A in the case of ritonavir-boosted 
lopinavir therapy [28,31,32], or I82L in the case of treatment with ritonavir-boosted tipranavir 
[13].  In addition to the limited knowledge about how to treat and interpret results from 
genotypic resistance assays in HIV-2 infection, therapeutic options might be limited in the long 
term due to inefficacy of several PR inhibitors (i.e. poor inhibitory activity and easy 
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development of resistance).  In this scenario, the design and development of novel specific 
drugs targeting the HIV-2 PR will gain importance, particularly with an increasing prevalence 
of HIV-2 infections.  Our current knowledge of the interactions between the HIV-1 PR and its 
inhibitors should provide a solid framework for the development of specific inhibitors of the 
HIV-2 PR through rational design.  In this context, the available crystal structures of HIV-2 
PR/inhibitor complexes should be an important aid to achieve that goal.
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LEGENDS TO FIGURES
Figure 1.  Targets for therapeutic intervention in the HIV life cycle.  Currently approved 
antiretroviral drugs block HIV infection at different steps of the viral life cycle: (i) virus entry
through their interaction with gp120 or gp41(i.e. maraviroc and enfuvirtide, respectively); (ii) 
reverse transcription (i.e. RT inhibitors); (iii) integration (i.e. integrase (IN) inhibitors such as 
raltegravir), and (iv) maturation (i.e. PR inhibitors that block the conversion of immature virus 
into mature infectious virions).
Figure 2.  Amino acid sequence comparison of HIV-1 and HIV-2 proteases of reference strains 
HXB2 (HIV-1) and ROD (HIV-2).  Identical residues are marked with red asterisks. Conserved 
structurally important regions are highlighted on a grey background.  Box A corresponds to the 
dimerization domain, box B to the active site region and the C-terminal triad, and box C 
indicates the flap region. Amino acid differences between HIV-1 and HIV-2 PRs at positions 
relevant for resistance to HIV-1 PR inhibitors are indicated [22]. Major and minor PR inhibitor 
resistance mutations occur at the positions highlighted in yellow and light blue, respectively.  
Highly polymorphic positions (≥ 20 % sequence variation) in the PR of HIV-2 subtype A 
isolates are indicated with blue letters.  HIV-2 PR residues appearing with a frequency above 4 
% are indicated below the reference sequence. The analysis of polymorphic sites in the HIV-2 
PR was based on 164 published sequences of HIV-2 isolates obtained from naïve patients [9-
14]. 
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Figure 3.  Crystallographic structures of human immunodeficiency virus proteases complexed 
with indinavir.  In panels (A) and (B), the two polypeptide chains of the human 
immunodeficiency virus type 2 protease are represented as ribbon diagrams (red and green).  
The inhibitor is shown in yellow using a CPK model.  The side chains chains of catalytic 
residues (Asp-25 in both subunits) are shown in blue. Atom coordinates were taken from PDB 
file 1HSH. Side and top views are shown in (A) and (B), respectively. (C) Crystal structure of 
human immunodeficiency virus type 1 protease complexed with indinavir (PDB file 1HSG). 
Figure 4.  Residues forming the substrate binding pocket of HIV proteases.  Schematic 
representation of an oligopeptide (SQNY↓PIV) that mimicks the HIV-1 Gag MA↓CA cleavage 
site, showing its potential interactions with the substrate binding site of the HIV-2 protease. 
Primes indicate residues in the second subunit of the dimer.  The relative size of each substrate 
is illustrated by the area enclosed by the curved line around each substrate side chain. Substrate 
binding residues that are commonly observed in HIV isolates with high-level resistance to one 
or more drugs are boxed, and the residue found in the wild-type HIV-1 is shown between 
parentheses.  The amino acid residues interacting with ritonavir, lopinavir and darunavir 
(inhibitors shown in white) in the crystal structures of HIV-1 PR complexes are indicated 
below.  Sequence positions of residues at less than 4 Å from the inhibitor are given.  Side 
chains and their corresponding amino acid are indicated for those residues located at less than 
3.5 Å of the inhibitor.     
Figure 5.  Inhibitors of human immunodeficiency virus type 1 (HIV-1) protease that are 
licensed to treat AIDS and AIDS-related malignancies.
